



## FEP Medical Policy Manual

### FEP 2.04.88 Genetic Testing for PTEN Hamartoma Tumor Syndrome

**Effective Policy Date: July 1, 2023**

**Original Policy Date: September 2013**

**Related Policies:**

None

## Genetic Testing for PTEN Hamartoma Tumor Syndrome

### Description

#### Description

The *PTEN* hamartoma tumor syndrome (PHTS) includes several syndromes with heterogeneous clinical symptoms, which may place individuals at an increased risk for the development of certain types of cancer. Genetic testing for *PTEN* can confirm a diagnosis of PHTS.

#### OBJECTIVE

The objective of this evidence review is to determine whether genetic testing improves the net health outcome in individuals with clinical signs and/or symptoms of a *PTEN* hamartoma tumor syndrome. This review does not evaluate testing for at-risk or asymptomatic individuals (see Benefit Application).

#### POLICY STATEMENT

Genetic testing for *PTEN* may be considered **medically necessary** to confirm the diagnosis when an individual has clinical signs of a *PTEN* hamartoma tumor syndrome.

Genetic testing for *PTEN* is considered **investigational** for all other indications.

## POLICY GUIDELINES

### Testing Strategy to Confirm a Diagnosis in a Proband

The order of testing to optimize yield would be (1) sequencing of *PTEN* exons 1-9 and flanking intronic regions. If no disease-associated variant is identified, perform (2) deletion/duplication analysis. If no disease-associated variant is identified, consider (3) promoter analysis, which detects disease-associated variants in approximately 10% of individuals with Cowden syndrome who do not have an identifiable disease-associated variant in the *PTEN* coding region.

### Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology - "pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign" - to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic

counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

## FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratory testing for *PTEN* variants is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

## RATIONALE

### Summary of Evidence

For individuals who have clinical signs and/or symptoms of a *PTEN* hamartoma tumor syndrome (PHTS) or who are asymptomatic with a first-degree relative with a PHTS and a known familial variant who receive genetic testing for a *PTEN* familial variant, the evidence includes case series and a large prospective study on the frequency of a *PTEN* variants in individuals meeting clinical criteria for a PHTS, and studies of cancer risk estimates in individuals with a *PTEN* disease-associated variant. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and morbid events. The published clinical validity of testing for the *PTEN* gene is variable. The true clinical validity is difficult to ascertain because the syndrome is defined by the presence of a *PTEN* disease-associated variant. The sensitivity of tests for Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome has been reported to be up to 80% and 60%, respectively. Direct evidence of the clinical utility of genetic testing for *PTEN* is lacking; however, confirming a diagnosis in a patient with clinical signs of a PHTS will lead to changes in clinical management by increasing surveillance to detect cancers associated with PHTS at an early and treatable stage. Although most cases of a PHTS occur in individuals with no known family history of PHTS, testing of at-risk relatives will identify those who should also undergo increased cancer surveillance. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### National Comprehensive Cancer Network

Current (v.2.2023 ), National Comprehensive Cancer Network guidelines on genetic/familial high-risk assessment for breast and ovarian cancer<sup>6</sup>, include Testing Criteria for Cowden Syndrome (CS)/*PTEN* Hamartoma Tumor Syndrome (PHTS) (CRIT-8 ) that recommend testing for:

- Individual from a family with a known *PTEN* pathogenic/likely pathogenic variant
- Individual with a personal history of Bannayan-Riley-Ruvalcaba syndrome (BRRS)
- Individual meeting clinical diagnostic criteria for CS/PHTS

- Individual not meeting clinical diagnostic criteria for CS/PHTS with a personal history of: Adult Lhermitte-Duclos disease (cerebellar tumors); or autism spectrum disorder and macrocephaly; or 2 or more biopsy-proven trichilemmomas; or 2 or more major criteria (1 must be macrocephaly); or 3 major criteria, without macrocephaly; or 1 major criteria, without macrocephaly; or 1 major and  $\geq 3$  minor criteria; or  $\geq 4$  minor criteria
- At-risk individual with a relative with a clinical diagnosis of CS/PHTS or BRRS for whom testing has not been performed. The at-risk individual must have the following: Any 1 major criterion or 2 minor criteria.
- *PTEN* pathogenic/likely pathogenic variant detected by tumor profiling on any tumor type in the absence of germline analysis.

Additionally, the following is recommended for Cowden syndrome management (see Table 1).

**Table 1. NCCN Guidelines on Cowden Syndrome / *PTEN* Hamartoma Tumor Syndrome Management**

Populations	Recommendations
Women	<ul style="list-style-type: none"> <li>• Breast awareness starting at age 18 years.</li> </ul>
	<ul style="list-style-type: none"> <li>• Clinical breast exam every 6 to 12 months, starting at age 25 years or 5 to 10 years before the earliest known breast cancer in the family (whichever comes first).</li> </ul>
	<ul style="list-style-type: none"> <li>• Breast screening:</li> </ul>
	<ul style="list-style-type: none"> <li>• Annual mammography with consideration of tomosynthesis and breast MRI screening starting at age 35 years or 10 years before the earliest known breast cancer in family (whichever comes first).</li> </ul>
	<ul style="list-style-type: none"> <li>• Age &gt;75, management should be considered on an individual basis.</li> </ul>
	<ul style="list-style-type: none"> <li>• For women with a <i>PTEN</i> mutation [disease-associated variant] who are treated for breast cancer, screening of remaining breast tissue with annual mammography and breast MRI should continue.</li> </ul>
	<ul style="list-style-type: none"> <li>• For endometrial cancer screening, encourage patient education and prompt response to symptoms. Consider annual random endometrial biopsies and/or ultrasound beginning at age 30 to 35 years.</li> </ul>
	<ul style="list-style-type: none"> <li>• Discuss risk-reducing mastectomy and hysterectomy and counsel regarding degree of protection, extent of cancer risk, and reconstructive options</li> </ul>
Men and women	<ul style="list-style-type: none"> <li>• Annual comprehensive physical exam starting at age 18 years or 5 years before the youngest age of diagnosis of a component cancer in the family (whichever comes first), with particular attention to breast and thyroid exam.</li> </ul>

	<ul style="list-style-type: none"> <li>Annual thyroid ultrasound starting at age 7. This may also be considered for children at 50% risk of inheriting a known mutation whose parents wish to delay genetic testing until age 18 years..</li> </ul>
	<ul style="list-style-type: none"> <li>Colonoscopy, starting at age 35 years, unless symptomatic or a close relative with colon cancer under age 40 years. Colonoscopy should be done every 5 years or more frequently if patient is symptomatic or polyps found.</li> </ul>
	<ul style="list-style-type: none"> <li>Dermatologic management may be indicated for some patients.</li> </ul>
	<ul style="list-style-type: none"> <li>Consider renal ultrasound starting at age 40 years, then every 1 to 2 years.</li> </ul>
	<ul style="list-style-type: none"> <li>Consider psychomotor assessment in children at diagnosis and brain MRI if there are symptoms</li> </ul>
	<ul style="list-style-type: none"> <li>Education regarding signs and symptoms of cancer</li> </ul>
Relatives	<ul style="list-style-type: none"> <li>Advise about possible inherited cancer risk to relatives, options for risk assessment, and management</li> </ul>
	<ul style="list-style-type: none"> <li>Recommend genetic counseling and consideration of genetic testing for at-risk relatives</li> </ul>
Reproductive options	<ul style="list-style-type: none"> <li>For women of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including preimplantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies</li> </ul>

MRI: magnetic resonance imaging; PHTS: *PTEN* hamartoma tumor syndrome.

## U.S. Preventive Services Task Force Recommendations

No **U.S. Preventive Services Task Force** recommendations for genetic testing for *PTEN* hamartoma tumor syndrome have been identified.

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## REFERENCES

- Eng C. PTEN Hamartoma Tumor Syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews. Seattle, WA: University of Washington; 2016.
- Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. Jan 15 2012; 18(2): 400-7. PMID 22252256
- Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. Apr 2013; 50(4): 255-63. PMID 23335809

4. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. *Eur J Hum Genet.* Nov 2008; 16(11): 1289-300. PMID 18781191
5. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst.* Nov 06 2013; 105(21): 1607-16. PMID 24136893
6. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high risk assessment: breast and ovarian. Version 2.2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_bop.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf) Accessed January 28, 2023.
7. Biesecker L. The challenges of Proteus syndrome: diagnosis and management. *Eur J Hum Genet.* Nov 2006; 14(11): 1151-7. PMID 16883308
8. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. *J Med Genet.* Aug 2011; 48(8): 505-12. PMID 21659347
9. ARUP Laboratories. Laboratory Test Directory: PTEN-Related Disorder (PTEN) Sequencing. n.d.; <http://td.aruplab.com/tests/pub/2002722> Accessed January 28, 2023
10. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet.* Mar 1998; 7(3): 507-15. PMID 9467011
11. Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. *Hum Mol Genet.* Aug 1999; 8(8): 1461-72. PMID 10400993
12. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. *J Med Genet.* May 2004; 41(5): 323-6. PMID 15121767

## POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2013	New policy	Genetic testing for a PTEN mutation may be considered medically necessary to confirm the diagnosis when a patient has clinical signs of a PTEN hamartoma tumor syndrome.
June 2014	Replace policy	Policy updated with literature; reference 1 added. Clarification of testing strategy in Policy Guidelines.
June 2015	Replace policy	Policy updated with literature review; no references added. Policy statements unchanged.
June 2018	Replace policy	Policy updated with literature review through December 11, 2017; references 1-3 added. Objective Statement added. Policy statements unchanged.
June 2019	Replace policy	Policy updated with literature review through December 10, 2018; no references added. Policy statements unchanged.
June 2020	Replace policy	Policy updated with literature review through December 10, 2019; no references added. Added NCCN testing criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome (Version 1.2020). Policy statement unchanged.
June 2021	Replace policy	Policy updated with literature review through December 14, 2020; no references added. Updated NCCN testing criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome (Version 2.2021). Policy statement unchanged.
June 2022	Replace policy	Policy updated with literature review through November 15, 2021; no references added. Updated NCCN testing criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome. Policy statements unchanged.
June 2023	Replace policy	Policy updated with literature review through November 14, 2023; no references added. Minor editorial refinements to policy statements; intent unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.